Search…
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Search...
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Home
>
Latest
Lates News
25/05/2026
Market news: The hospital stated that Lula can carry out daily activities normally, without any restrictions.
Latest
2 m ago
Li Qiang Meets with Serbian President Vucic
3 m ago
Jinhe Business Management: Clarification Announcement on Rumors of Lawsuit with Water Vapor Stone
4 m ago
Wuhan Research Institute of Technology (300550.SZ): Planning for changes in controlling ownership matters. Stock trading halted.
5 m ago
The "Private Enterprise Entering the Border" initiative has signed a total of 132 projects in Dandong, Liaoning.
5 m ago
US pharmaceutical company LLY.N announced that its experimental gene editing therapy for treating high cholesterol has shown positive results in a Phase 1b clinical trial. The company stated that in the Phase 1b study aimed at adults with heterozygous familial hypercholesterolemia or early-onset coronary artery disease, a single administration of the therapy called Verve-102 resulted in a reduction of PCSK9 protein levels by up to 88% and a decrease in low-density lipoprotein cholesterol by up to 62%. The therapy utilizes in vivo base editing technology to effectively shut down the PCSK9 gene in the liver, mimicking a natural genetic variation that can prevent heart disease. The US Food and Drug Administration (FDA) has granted fast track designation to the therapy. LLY.N reported that the therapy has a duration of effect lasting up to 18 months and no serious adverse events related to the treatment have been reported. The company plans to start Phase 2 clinical trials of Verve-102 by the end of this year.
See all latest
